ALKS

ALKS

USD

Alkermes plc Ordinary Shares

$30.480+0.480 (1.600%)

वास्तविक समय मूल्य

Healthcare
Drug Manufacturers - Specialty & Generic
आयरलैंड

मूल्य चार्ट

Loading Chart...

मुख्य मीट्रिक्स

बाजार मीट्रिक्स
कंपनी के मौलिक सिद्धांत
ट्रेडिंग आँकड़े

बाजार मीट्रिक्स

खुलना

$30.000

उच्च

$30.630

कम

$29.770

मात्रा

0.42M

कंपनी के मौलिक सिद्धांत

बाजार पूंजीकरण

5.0B

उद्योग

Drug Manufacturers - Specialty & Generic

देश

Ireland

ट्रेडिंग आँकड़े

औसत मात्रा

2.00M

एक्सचेंज

NMS

मुद्रा

USD

52-सप्ताह रेंज

कम $25.17वर्तमान $30.480उच्च $36.45

संबंधित समाचार

Analyst Upgrades

Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42

Wells Fargo analyst Benjamin Burnett maintains Alkermes with a Overweight and lowers the price target from $44 to $42.

और देखें
Wells Fargo Maintains Overweight on Alkermes, Lowers Price Target to $42
Analyst Upgrades

Needham Maintains Buy on Alkermes, Raises Price Target to $44

Needham analyst Ami Fadia maintains Alkermes with a Buy and raises the price target from $43 to $44.

और देखें
Needham Maintains Buy on Alkermes, Raises Price Target to $44
PR Newswire

Alkermes plc Reports Third Quarter 2025 Financial Results

Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2025. "Alkermes delivered another successful quarter, achieving ...

और देखें
Alkermes plc Reports Third Quarter 2025 Financial Results
Analyst Upgrades

Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45

Mizuho analyst Uy Ear maintains Alkermes with a Outperform and raises the price target from $40 to $45.

और देखें
Mizuho Maintains Outperform on Alkermes, Raises Price Target to $45
Analyst Upgrades

Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45

Piper Sandler analyst David Amsellem reiterates Alkermes with a Overweight and raises the price target from $38 to $45.

और देखें
Piper Sandler Reiterates Overweight on Alkermes, Raises Price Target to $45
Analyst Upgrades

RBC Capital Maintains Outperform on Alkermes, Raises Price Target to $47

RBC Capital analyst Leonid Timashev maintains Alkermes with a Outperform and raises the price target from $45 to $47.

अपडेट रहें

मूल्य अलर्ट सेट करें, AI विश्लेषण अपडेट और वास्तविक समय बाजार समाचार प्राप्त करें।